Targeting the aryl hydrocarbon receptor by gut phenolic metabolites

Detalhes bibliográficos
Autor(a) principal: Pinto, Catarina J.G.
Data de Publicação: 2023
Outros Autores: Ávila-Gálvez, María Ángeles, Lian, Yilong, Moura-Alves, Pedro, Nunes dos Santos, Cláudia
Tipo de documento: Outros
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/150335
Resumo: Funding Information: Several clinical trials support that the specific CD exclusion diet and the UC exclusion diet are well-established procedures to achieve remission in those patients [166]. Besides, carbohydrate diet patterns have been shown to help clinical remission in paediatric patients with CD [167,168]. However, these diets are very restrictive diets depriving people of a large number of foods. The Mediterranean diet has gained popularity to prevent and/or treat IBD due to its potential in decreasing inflammatory markers and mortality in IBD patients [169,170]. Regular consumption of a Mediterranean diet in healthy people decreases the risk of developing IBD associated with specific gut microbiome regulation as well as a reduction in gut inflammatory markers (e.g., calprotectin) [171]. The beneficial effects of long-lasting adherence to the Mediterranean diet have been attributed to specific components like (poly)phenols [172], which are very abundant in this diet and are associated with immunomodulatory properties and a reduced incidence of inflammation.This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 804229. iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344), which is co-funded by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Ciência e do Ensino Superior, through national funds, and by FEDER under the PT2020 Partnership Agreement, is acknowledged (UIDB/04462/2020 and UIDP/04462/2020). Y. Lian and P. Moura-Alves acknowledge the support of the Ludwig Institute for Cancer Research- Core Award, and P. Moura-Alves the H2020-WIDESPREAD-2018-951921- ImmunoHUB. Authors would like to acknowledge FCT for financial support of C. J. G. Pinto (2022.11465. BD). Funding Information: This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 804229 . iNOVA4Health Research Unit ( LISBOA-01-0145-FEDER-007344 ), which is co-funded by Fundação para a Ciência e Tecnologia (FCT) / Ministério da Ciência e do Ensino Superior , through national funds, and by FEDER under the PT2020 Partnership Agreement, is acknowledged ( UIDB/04462/2020 and UIDP/04462/2020 ). Y. Lian and P. Moura-Alves acknowledge the support of the Ludwig Institute for Cancer Research- Core Award , and P. Moura-Alves the H2020-WIDESPREAD-2018-951921- ImmunoHUB . Authors would like to acknowledge FCT for financial support of C. J. G. Pinto ( 2022.11465 . BD). Publisher Copyright: © 2023 The Authors
id RCAP_1b85e1670fd97239878ec936713e624d
oai_identifier_str oai:run.unl.pt:10362/150335
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Targeting the aryl hydrocarbon receptor by gut phenolic metabolitesA strategy towards gut inflammationAHRDietary (poly)phenolsInflammatory bowel diseaseMicrobiotaOrganic ChemistryClinical BiochemistryFunding Information: Several clinical trials support that the specific CD exclusion diet and the UC exclusion diet are well-established procedures to achieve remission in those patients [166]. Besides, carbohydrate diet patterns have been shown to help clinical remission in paediatric patients with CD [167,168]. However, these diets are very restrictive diets depriving people of a large number of foods. The Mediterranean diet has gained popularity to prevent and/or treat IBD due to its potential in decreasing inflammatory markers and mortality in IBD patients [169,170]. Regular consumption of a Mediterranean diet in healthy people decreases the risk of developing IBD associated with specific gut microbiome regulation as well as a reduction in gut inflammatory markers (e.g., calprotectin) [171]. The beneficial effects of long-lasting adherence to the Mediterranean diet have been attributed to specific components like (poly)phenols [172], which are very abundant in this diet and are associated with immunomodulatory properties and a reduced incidence of inflammation.This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 804229. iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344), which is co-funded by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Ciência e do Ensino Superior, through national funds, and by FEDER under the PT2020 Partnership Agreement, is acknowledged (UIDB/04462/2020 and UIDP/04462/2020). Y. Lian and P. Moura-Alves acknowledge the support of the Ludwig Institute for Cancer Research- Core Award, and P. Moura-Alves the H2020-WIDESPREAD-2018-951921- ImmunoHUB. Authors would like to acknowledge FCT for financial support of C. J. G. Pinto (2022.11465. BD). Funding Information: This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 804229 . iNOVA4Health Research Unit ( LISBOA-01-0145-FEDER-007344 ), which is co-funded by Fundação para a Ciência e Tecnologia (FCT) / Ministério da Ciência e do Ensino Superior , through national funds, and by FEDER under the PT2020 Partnership Agreement, is acknowledged ( UIDB/04462/2020 and UIDP/04462/2020 ). Y. Lian and P. Moura-Alves acknowledge the support of the Ludwig Institute for Cancer Research- Core Award , and P. Moura-Alves the H2020-WIDESPREAD-2018-951921- ImmunoHUB . Authors would like to acknowledge FCT for financial support of C. J. G. Pinto ( 2022.11465 . BD). Publisher Copyright: © 2023 The AuthorsThe Aryl Hydrocarbon Receptor (AHR) is a ligand-dependent transcription factor able to control complex transcriptional processes in several cell types, which has been correlated with various diseases, including inflammatory bowel diseases (IBD). Numerous studies have described different compounds as ligands of this receptor, like xenobiotics, natural compounds, and several host-derived metabolites. Dietary (poly)phenols have been studied regarding their pleiotropic activities (e.g., neuroprotective and anti-inflammatory), but their AHR modulatory capabilities have also been considered. However, dietary (poly)phenols are submitted to extensive metabolism in the gut (e.g., gut microbiota). Thus, the resulting gut phenolic metabolites could be key players modulating AHR since they are the ones that reach the cells and may exert effects on the AHR throughout the gut and other organs. This review aims at a comprehensive search for the most abundant gut phenolic metabolites detected and quantified in humans to understand how many have been described as AHR modulators and what could be their impact on inflammatory gut processes. Even though several phenolic compounds have been studied regarding their anti-inflammatory capacities, only 1 gut phenolic metabolite, described as AHR modulator, has been evaluated on intestinal inflammatory models. Searching for AHR ligands could be a novel strategy against IBD.iNOVA4Health - pólo NMSNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNPinto, Catarina J.G.Ávila-Gálvez, María ÁngelesLian, YilongMoura-Alves, PedroNunes dos Santos, Cláudia2023-03-10T22:52:02Z2023-052023-05-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttp://hdl.handle.net/10362/150335eng2213-2317PURE: 54506027https://doi.org/10.1016/j.redox.2023.102622info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T18:09:49Zoai:run.unl.pt:10362/150335Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T18:09:49Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
A strategy towards gut inflammation
title Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
spellingShingle Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
Pinto, Catarina J.G.
AHR
Dietary (poly)phenols
Inflammatory bowel disease
Microbiota
Organic Chemistry
Clinical Biochemistry
title_short Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
title_full Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
title_fullStr Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
title_full_unstemmed Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
title_sort Targeting the aryl hydrocarbon receptor by gut phenolic metabolites
author Pinto, Catarina J.G.
author_facet Pinto, Catarina J.G.
Ávila-Gálvez, María Ángeles
Lian, Yilong
Moura-Alves, Pedro
Nunes dos Santos, Cláudia
author_role author
author2 Ávila-Gálvez, María Ángeles
Lian, Yilong
Moura-Alves, Pedro
Nunes dos Santos, Cláudia
author2_role author
author
author
author
dc.contributor.none.fl_str_mv iNOVA4Health - pólo NMS
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Pinto, Catarina J.G.
Ávila-Gálvez, María Ángeles
Lian, Yilong
Moura-Alves, Pedro
Nunes dos Santos, Cláudia
dc.subject.por.fl_str_mv AHR
Dietary (poly)phenols
Inflammatory bowel disease
Microbiota
Organic Chemistry
Clinical Biochemistry
topic AHR
Dietary (poly)phenols
Inflammatory bowel disease
Microbiota
Organic Chemistry
Clinical Biochemistry
description Funding Information: Several clinical trials support that the specific CD exclusion diet and the UC exclusion diet are well-established procedures to achieve remission in those patients [166]. Besides, carbohydrate diet patterns have been shown to help clinical remission in paediatric patients with CD [167,168]. However, these diets are very restrictive diets depriving people of a large number of foods. The Mediterranean diet has gained popularity to prevent and/or treat IBD due to its potential in decreasing inflammatory markers and mortality in IBD patients [169,170]. Regular consumption of a Mediterranean diet in healthy people decreases the risk of developing IBD associated with specific gut microbiome regulation as well as a reduction in gut inflammatory markers (e.g., calprotectin) [171]. The beneficial effects of long-lasting adherence to the Mediterranean diet have been attributed to specific components like (poly)phenols [172], which are very abundant in this diet and are associated with immunomodulatory properties and a reduced incidence of inflammation.This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 804229. iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344), which is co-funded by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Ciência e do Ensino Superior, through national funds, and by FEDER under the PT2020 Partnership Agreement, is acknowledged (UIDB/04462/2020 and UIDP/04462/2020). Y. Lian and P. Moura-Alves acknowledge the support of the Ludwig Institute for Cancer Research- Core Award, and P. Moura-Alves the H2020-WIDESPREAD-2018-951921- ImmunoHUB. Authors would like to acknowledge FCT for financial support of C. J. G. Pinto (2022.11465. BD). Funding Information: This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 804229 . iNOVA4Health Research Unit ( LISBOA-01-0145-FEDER-007344 ), which is co-funded by Fundação para a Ciência e Tecnologia (FCT) / Ministério da Ciência e do Ensino Superior , through national funds, and by FEDER under the PT2020 Partnership Agreement, is acknowledged ( UIDB/04462/2020 and UIDP/04462/2020 ). Y. Lian and P. Moura-Alves acknowledge the support of the Ludwig Institute for Cancer Research- Core Award , and P. Moura-Alves the H2020-WIDESPREAD-2018-951921- ImmunoHUB . Authors would like to acknowledge FCT for financial support of C. J. G. Pinto ( 2022.11465 . BD). Publisher Copyright: © 2023 The Authors
publishDate 2023
dc.date.none.fl_str_mv 2023-03-10T22:52:02Z
2023-05
2023-05-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/150335
url http://hdl.handle.net/10362/150335
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2213-2317
PURE: 54506027
https://doi.org/10.1016/j.redox.2023.102622
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545921290829824